BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19907030)

  • 1. Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
    Iwata D; Kitaichi N; Miyazaki A; Iwabuchi K; Yoshida K; Namba K; Ozaki M; Ohno S; Umezawa K; Yamashita K; Todo S; Ishida S; Onoé K
    Invest Ophthalmol Vis Sci; 2010 Apr; 51(4):2077-84. PubMed ID: 19907030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate.
    Kitamei H; Iwabuchi K; Namba K; Yoshida K; Yanagawa Y; Kitaichi N; Kitamura M; Ohno S; Onoé K
    J Leukoc Biol; 2006 Jun; 79(6):1193-201. PubMed ID: 16574770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
    Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S; Yamashita K; Aoyagi T; Haga S; Suzuki T; Itoh T; Taniguchi M; Shimamura T; Furukawa H; Ozaki M; Umezawa K; Todo S
    Transplantation; 2006 Dec; 82(12):1720-7. PubMed ID: 17198266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
    Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response.
    Wu Y; Wang Y; Zhong C; Li Y; Li X; Sun B
    Int Immunopharmacol; 2003 Oct; 3(10-11):1457-65. PubMed ID: 12946442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K; Nanki T; Miyasaka N; Umezawa K; Kubota T
    Arthritis Res Ther; 2005; 7(6):R1348-59. PubMed ID: 16277688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
    Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
    Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
    Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
    Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity.
    Zhang X; Ren X; Li G; Jiao C; Zhang L; Zhao S; Wang J; Han ZC; Li X
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3143-52. PubMed ID: 21296818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102.
    Ohsugi T; Kumasaka T; Ishida A; Ishida T; Horie R; Watanabe T; Umezawa K; Yamaguchi K
    Leuk Res; 2006 Jan; 30(1):90-7. PubMed ID: 16002138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
    Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
    Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
    Kohno H; Sakai T; Saito S; Okano K; Kitahara K
    Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K; Kikuchi E; Kosugi M; Horiguchi Y; Matsumoto K; Kanai K; Suzuki E; Miyajima A; Nakagawa K; Tachibana M; Umezawa K; Oya M
    Urology; 2010 Apr; 75(4):805-12. PubMed ID: 20156648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of experimental autoimmune uveoretinitis with anti-macrophage migration inhibitory factor antibodies.
    Kitaichi N; Matsuda A; Kotake S; Namba K; Tagawa Y; Sasamoto Y; Ogasawara K; Iwabuchi K; Onoé K; Matsuda H; Nishihira J
    Curr Eye Res; 2000 Feb; 20(2):109-14. PubMed ID: 10617911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
    Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
    Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
    Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
    Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.